Comparing FET Guided by ERA Vs Standard Timing in Patients with Recurrent Implantation Failure

Launched by THE UNIVERSITY OF HONG KONG · Dec 30, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to help women who have trouble getting pregnant after multiple attempts with in vitro fertilization (IVF). It's specifically studying whether a procedure called endometrial receptivity analysis (ERA) can improve pregnancy rates for these women. The ERA test helps determine the best timing for placing an embryo in the uterus, which could make it more likely to succeed. Women who join the study will have a small sample taken from the lining of their uterus and will then be randomly assigned to either follow ERA-guided timing or the standard timing for their embryo transfer.

To be eligible for this study, women must be under 40 years old, have a healthy weight, and have experienced repeated failures with embryo transfers. They should also have at least one high-quality frozen embryo ready for transfer. The trial is currently recruiting participants, and those who join can expect to follow a careful plan for their treatment, which might help improve their chances of becoming pregnant. This study is important because it could provide valuable information on whether using ERA can truly make a difference for women facing recurrent implantation failure.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Women with recurrent implantation failure
• • 2. Women aged \< 40 years
• • 3. Body mass index of women between 18.5 (inclusive) and 30 (exclusive) kg/m²
• • 4. Women with at least one high quality frozen blastocyst (BB grade or above) and planning to undergo a single blastocyst transfer
• • 5. Women who will give written informed consent
• Exclusion Criteria:
• • 1. Women with recurrent pregnancy loss (3 or more biochemical or spontaneous miscarriages)
• • 2. Either partner with known chromosomal abnormalities including balanced translocations
• • 3. Women undergoing preimplantation genetic testing
• • 4. Women with endometrial thickness \< 7 mm in the IVF cycle
• • 5. Women with a confirmed diagnosis of stage III-IV endometriosis or adenomyosis affecting uterine cavity morphology
• • 6. Women with a confirmed diagnosis of antiphospholipid syndrome
• • 7. Pathologies affecting the uterine cavity, including polyps, submucosal fibroids, intramural fibroids \> 4 cm, or hydrosalpinx